Mark Buyyounouski, MD, MS, FASTRO

4.9/5

106 Patient Ratings

96 Patient Reviews

Professional Summary

Education & Certifications

Medical Education: Rutgers New Jersey Medical School (2000) NJ
Internship: Saint Barnabas Medical Center (2001) NJ
Board Certification: American Board of Radiology, Radiation Oncology (2006)
- Residency: Fox Chase Cancer Center (2005) PA

View More Education & Certifications

Honors & Awards

America’s Best Prostate Cancer Oncologists 2024, Newsweek (2024)
Castle Connolly Top Doc - 12 years, Castle Connolly (2014-2026)
Fellow, American Society for Radiation Oncology (ASTRO) (2022)
- RSNA Seed Grant, Radiological Society of North America Roentgen (RSNA) (2008)
- Roentgen Resident/Fellow Research Award, Radiological Society of North America Roentgen (RSNA) (2003, 2005)
- Travel Grant to attend National Cancer Institute Radiation Research Program, American Society for Radiation Oncology (ASTRO) (2005)

View More Honors & Awards

Memberships

Member, American Society of Radiation Oncology (ASTRO) Health Policy Committee (2007 - 2019)
Member, American Board of Radiology (ABR) Genitourinary Committee for Exams (2009 - 2021)
Member, American Brachytherapy Society (ABS) Board of Directors (2010 - 2013)
- Member, National Comprehensive Cancer Committee (NCCN) Guideline Committee (2010 - Present)
- Member, American Joint Cancer Committee (AJCC) Cancer Staging Expert Panel (2014 - Present)

View More Memberships

Administrative Appointments

Director, Billing, Radiation Oncology (2014 - 2021)
Director, Clinical Operations, Radiation Oncology (2015 - 2016)
Director, Genitourinary Cancers, Radiation Oncology (2013 - Present)

Publications

Testicular Cancer Clinical Practice Guidelines in Oncology
Motzer, R. J., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., Buyyounouski, M. K., … Wilder, R. B. (2012). Testicular Cancer Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(4), 502–35.
Dosimetric comparison of 4D and 3 multi-phase CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer
Wang, L., Jin, L., Hayes, S., Paskalev, K., Buyyounouski, M., & Feigenberg, S. (2007). Dosimetric comparison of 4D and 3 multi-phase CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer. MEDICAL PHYSICS, 34(6), 2384–2384.
Primary Prostate Radiation Therapy: Where Are We Failing?
Huang, K. T., Walker, G., Stoyanova, R., SANDLER, K., Horwitz, E., Buyyounouski, M. K., & Pollack, A. (2012). Primary Prostate Radiation Therapy: Where Are We Failing? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S182–S182.
- A Novel Methodology to Predict Late Urinary Toxicity Following Prostate Radiation Therapy-based on Bladder Wall Dosimetry
  Ahmed, A., Egleston, B., Alcantara, P., Pollack, A., Li, L., Horwitz, E. M., & Buyyounouski, M. K. (2012). A Novel Methodology to Predict Late Urinary Toxicity Following Prostate Radiation Therapy-based on Bladder Wall Dosimetry. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S418–S419.
- Prospective Validation of Diagnostic Tumor Tissue Ki-67 as the Most Significant Predictor of Outcome in Men Treated for Prostate Cancer on a Randomized Trial
  Pollack, A., Walker, G., Stoyanova, R., Khor, L., Horwitz, E., & Buyyounouski, M. (2012). Prospective Validation of Diagnostic Tumor Tissue Ki-67 as the Most Significant Predictor of Outcome in Men Treated for Prostate Cancer on a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S25–S26.
- Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low- and Intermediate-risk Prostate Cancer (CaP)?
  Martin, J. M., Sopka, D. M., Ruth, K. J., Buyyounouski, M. K., Kutikov, A., Sobczak, M. L., … Horwitz, E. M. (2012). Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low- and Intermediate-risk Prostate Cancer (CaP)? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S185–S186.
- Untitled Reply
  Turaka, A., Buyyounouski, M. K., Horwitz, E. M., & Movsas, B. (2013). Untitled Reply. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 86(1), 6–7.
- Stratifying intermediate-risk patients for radiotherapy
  Buyyounouski, M. K. (2013). Stratifying intermediate-risk patients for radiotherapy. NATURE REVIEWS UROLOGY, 10(8), 438–39.
- Toxicity and Biochemical Failure Following Image-Guided Prostate Intensity Modulated Radiation Therapy: Fiducial Markers Versus Electromagnetic Transponders
  Chang, L., Li, T., Horwitz, E., Chen, D. Y. T., Viterbo, R., Kutikov, A., … Buyyounouski, M. K. (2013). Toxicity and Biochemical Failure Following Image-Guided Prostate Intensity Modulated Radiation Therapy: Fiducial Markers Versus Electromagnetic Transponders. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S368–S369.
- Improved Outcomes in Men Treated With Adjuvant or Early Salvage Postprostatectomy IMRT or 3DCRT at a Single Institution
  Murphy, C., Uzzo, R. G., Ruth, K. J., Viterbo, R., Plimack, E., Buyyounouski, M. K., … Greenberg, R. E. (2013). Improved Outcomes in Men Treated With Adjuvant or Early Salvage Postprostatectomy IMRT or 3DCRT at a Single Institution. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S378–S378.
- Effectiveness and Timing of Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Carcinoma (LS-SCLC) Patients: A Single Institution Experience
  Turaka, A., Li, T., Naik, M. J., Unger, M., King, E., Shah, P. C., … Buyyounouski, M. K. (2013). Effectiveness and Timing of Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Carcinoma (LS-SCLC) Patients: A Single Institution Experience. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ATLANTA,GA,GA: ELSEVIER SCIENCE INC.
- Twice Daily Versus Once Daily Radiation Therapy in Unselected Limited-Stage Small Cell Lung Cancer Patients: "Medicine-Based" Evidence
  Turaka, A., Li, T., Naik, M. J., Unger, M., King, E., Shah, P. C., … Buyyounouski, M. K. (2013). Twice Daily Versus Once Daily Radiation Therapy in Unselected Limited-Stage Small Cell Lung Cancer Patients: "Medicine-Based" Evidence. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ATLANTA,GA,GA: ELSEVIER SCIENCE INC.
- CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques
  Chen, X., Xue, J., Chen, L., Buyyounouski, M. K., Horwitz, E. M., Wang, L., & Ma, C. (2013). CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S718–S718.
- Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy for Prostate Cancer
  Murphy, C., Ruth, K. J., Buyyounouski, M. K., Heller, S., Weinberg, D., Uzzo, R., … Horwitz, E. M. (2013). Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S356–S356.
- Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method
  Zaorsky, N. G., Li, T., Devarajan, K., Horwitz, E. M., & Buyyounouski, M. K. (2012). Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method. CANCER, 118(22), 5535–43.
- The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms
  Stoyanova, R., Pahlajani, N. H., Egleston, B. L., Buyyounouski, M. K., Chen, D. Y. T., Horwitz, E. M., & Pollack, A. (2013). The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. CANCER, 119(5), 1080–1088.
- A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
  Sperduto, P. W., Wang, M., Robins, H. I., Schell, M. C., Werner-Wasik, M., Komaki, R., … Mehta, M. P. (2013). A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. CHICAGO,IL,IL: ELSEVIER SCIENCE INC.
- The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801
  Lawrence, Y. R., Paulus, R., Langer, C., Werner-Wasik, M., Buyyounouski, M. K., Komaki, R., … Movsas, B. (2013). The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. LUNG CANCER, 80(3), 298–305.
- A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints
  Ahmed, A. A., Egleston, B., Alcantara, P., Li, L., Pollack, A., Horwitz, E. M., & Buyyounouski, M. K. (2013). A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 86(4), 709–715.
- Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?
  Townsend, N. C., Ruth, K., Al-Saleem, T., Horwitz, E. M., Sobczak, M., Uzzo, R. G., … Buyyounouski, M. K. (2013). Gleason Scoring at a Comprehensive Cancer Center: What's The Difference? JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(7), 812–19.
- Reduction of prostate intrafractional motion from shortening the treatment time
  Li, J. S., Lin, M.-H., Buyyounouski, M. K., Horwitz, E. M., & Ma, C.-M. (2013). Reduction of prostate intrafractional motion from shortening the treatment time. PHYSICS IN MEDICINE AND BIOLOGY, 58(14), 4921–32.
- Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial
  Mitin, T., Hunt, D., Shipley, W. U., Kaufman, D. S., Uzzo, R., Wu, C.-L., … Zietman, A. L. (2013). Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. LANCET ONCOLOGY, 14(9), 863–872.
- Magnetic Resonance Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations
  Hossain, M., Richardson, T., Buyyounouski, M. K., Schirmer, T., Noeske, R., Chen, L., & Ma, C. (2012). Magnetic Resonance Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations. MEDICAL PHYSICS, 39(6), 3639–3640.
- How Certain Can the Real-Time Plan Predict the Post Dosimetry for Prostate Seed Implant?
  Li, J. S., Buyyounouski, M., Horwitz, E., & Ma, C.-M. (2012). How Certain Can the Real-Time Plan Predict the Post Dosimetry for Prostate Seed Implant? MEDICAL PHYSICS, 39(6), 3933–3933.
- Role of Radiation Therapy for Malignant Thymoma: A Single Institution Experience
  Turaka, A., Li, T., Scott, W. J., Borghaei, H., Shah, P. C., & Buyyounouski, M. K. (2012). Role of Radiation Therapy for Malignant Thymoma: A Single Institution Experience. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. BOSTON,MA,MA: ELSEVIER SCIENCE INC.
- Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy for Men With Prostate Cancer Treated on a Randomized Trial
  Stoyanova, R., Walker, G., SANDLER, K., Khor, L., Horwitz, E., Buyyounouski, M., & Pollack, A. (2012). Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy for Men With Prostate Cancer Treated on a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S60–S60.
- Recursive Partitioning Analysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup Risk Categories
  Townsend, N. C., Ruth, K., Buyyounouski, M., Kutikov, A., Viterbo, R., Sobczak, M., & Horwitz, E. M. (2012). Recursive Partitioning Analysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup Risk Categories. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S183–S183.
- Is Use of Radiation Therapy for Stage II Malignant Thymoma A Controversy?
  Turaka, A., Li, T., Scott, W. J., Shah, P. C., & Buyyounouski, M. K. (2012). Is Use of Radiation Therapy for Stage II Malignant Thymoma A Controversy? JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Role of Radiation Therapy for Malignant Thymoma: A Single Institution Experience
  Turaka, A., Li, T., Scott, W. J., Borghaei, H., Shah, P. C., & Buyyounouski, M. K. (2012). Role of Radiation Therapy for Malignant Thymoma: A Single Institution Experience. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer
  Klayton, T. L., Ruth, K., Horwitz, E. M., Uzzo, R. G., Kutikov, A., Chen, D. Y. T., … Buyyounouski, M. K. (2011). Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. RADIOTHERAPY AND ONCOLOGY, 101(3), 508–12.
- Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results
  Turaka, A., Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Greenberg, R. E., & Movsas, B. (2012). Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(3), E433–E439.
- RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON SCORE 8 TO 10 PROSTATE CANCER
  Pahlajani, N., Ruth, K. J., Buyyounouski, M. K., Chen, D. Y. T., Horwitz, E. M., Hanks, G. E., … Pollack, A. (2012). RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON SCORE 8 TO 10 PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(5), 1949–56.
- Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate
  Hossain, M., Schirmer, T., Richardson, T., Chen, L., Buyyounouski, M. K., & Ma, C. M. (2012). Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(1), 451–58.
- Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy
  Lubbe, W., Cohen, R., Sharma, N., Ruth, K., Peters, R., Li, J., … Horwitz, E. (2012). Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy. BRACHYTHERAPY, 11(3), 209–13.
- An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee
  Allen, A. M., Pawlicki, T., Dong, L., Fourkal, E., Buyyounouski, M., Cengel, K., … Konski, A. A. (2012). An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. RADIOTHERAPY AND ONCOLOGY, 103(1), 8–11.
- Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer
  Buyyounouski, M. K., Pickles, T., Kestin, L. L., Allison, R., & Williams, S. G. (2012). Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(15), 1857–63.
- Radiotherapy Treatment Planning for Testicular Seminoma
  Wilder, R. B., Buyyounouski, M. K., Efstathiou, J. A., & Beard, C. J. (2012). Radiotherapy Treatment Planning for Testicular Seminoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(4), E445–E452.
- A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update
  Buyyounouski, M. K., Davis, B. J., Prestidge, B. R., Shanahan, T. G., Stock, R. G., Grimm, P. D., … Horwitz, E. M. (2012). A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. BRACHYTHERAPY, 11(4), 299–305.
- Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer
  Keller, L. M. M., Buyyounouski, M. K., Sopka, D., Ruth, K., Klayton, T., Pollack, A., … Horwitz, E. M. (2012). Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer. UROLOGY, 80(2), 337–42.
- Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment
  Klayton, T., Price, R., Buyyounouski, M. K., Sobczak, M., Greenberg, R., Li, J., … Horwitz, E. M. (2012). Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), 130–36.
- Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy
  Zaorsky, N. G., Buyyounouski, M. K., Li, T., & Horwitz, E. M. (2012). Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), E13–E17.
- A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy
  Bagshaw, H. P., Ruth, K., Horwitz, E. M., Chen, D., & Buyyounouski, M. K. (2011). A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S211–S211.
- Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer
  Pollack, A., Walker, G., Buyyounouski, M., Horwitz, E., Price, R., Feigenberg, S., … Ma, C. (2011). Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S1–S1.
- Aspirin Use Reduces the Risk of Biochemical Failure and Distant Metastases Following Post-Prostatectomy Radiotherapy
  Cohen, R. J., Li, T., Horwitz, E. M., Peter, R., Uzzo, R. G., Viterbo, R., & Buyyounouski, M. K. (2011). Aspirin Use Reduces the Risk of Biochemical Failure and Distant Metastases Following Post-Prostatectomy Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S391–S392.
- The Impact of Gleason Scoring at a Comprehensive Cancer Center on the Ability to Predict Recurrence After Radiotherapy for Prostate Cancer
  Townsend, N. C., Ruth, K., Al-Saleem, T., Horwitz, E. M., Sobczak, M., Uzzo, R. G., … Buyyounouski, M. K. (2011). The Impact of Gleason Scoring at a Comprehensive Cancer Center on the Ability to Predict Recurrence After Radiotherapy for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S409–S410.
- Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With Conventional versus Hypofractionated Intensity Mediated Radiotherapy: A Phase III Hypofractionation Trial
  Jean-Pierre, P., Stoyanova, R., Penedo, F., Antoni, M., Abramowitz, M., Buyyounouski, M., & Pollack, A. (2011). Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With Conventional versus Hypofractionated Intensity Mediated Radiotherapy: A Phase III Hypofractionation Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S667–S667.
- Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment
  Klayton, T. L., Price, R., Buyyounouski, M. K., Sobczak, M., Greenberg, R. E., Li, J., … Horwitz, E. M. (2011). Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S101–S101.
- Genetic Polymorphisms of DNA Repair and Inflammatory Responses as Determinants of Late Toxicity in Prostate Cancer Patients Who Received Radiotherapy in a Randomized Trial
  Hu, J. J., Stoyanova, R., Deasy, J. O., Chung, R., Martin, E., Buyyounouski, M. K., … Pollack, A. (2011). Genetic Polymorphisms of DNA Repair and Inflammatory Responses as Determinants of Late Toxicity in Prostate Cancer Patients Who Received Radiotherapy in a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S109–S110.
- VMAT Reduces Moderate to High Integral Dose When Compared to Conventional IMRT for Treatment of Prostate Cancer
  Lubbe, W. J., Price, R., Ruth, K., Cherian, G., Kutikov, A., Chen, D., … Horwitz, E. (2011). VMAT Reduces Moderate to High Integral Dose When Compared to Conventional IMRT for Treatment of Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S446–S446.
- Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT
  Li, J., Buyyounouski, M. K., Lin, M., Horwitz, E. M., & Ma, C. (2011). Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S391–S391.
- Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a Randomized Hypofractionation Trial for Prostate Cancer
  Oh, J., Deasy, J., Stoyanova, R., Saleh, Z., Buyyounouski, M., Wong, H. P., … Pollack, A. (2011). Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a Randomized Hypofractionation Trial for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S156–S157.
- RADIOTHERAPY PSA nadir predicts long-term mortality
  Buyyounouski, M. K. (2010). RADIOTHERAPY PSA nadir predicts long-term mortality. NATURE REVIEWS CLINICAL ONCOLOGY, 7(4), 188–90.
- STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MANAGEMENT OF EARLY-STAGE, LOW- TO INTERMEDIATE-RISK PROSTATE CANCER: REPORT OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY EMERGING TECHNOLOGY COMMITTEE
  Buyyounouski, M. K., Price, R. A., Harris, E. E. R., Miller, R., Tome, W., Schefter, T., … Wallner, P. E. (2010). STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MANAGEMENT OF EARLY-STAGE, LOW- TO INTERMEDIATE-RISK PROSTATE CANCER: REPORT OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY EMERGING TECHNOLOGY COMMITTEE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76(5), 1297–1304.
- An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy
  Sharma, N. K., Cohen, R. J., Eade, T. N., Buyyounouski, M. K., Uzzo, R. G., Li, J., … Horwitz, E. M. (2010). An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy. BRACHYTHERAPY, 9(2), 126–30.
- STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: REPORT OF THE ASTRO EMERGING TECHNOLOGY COMMITTEE
  Buyyounouski, M. K., Balter, P., Lewis, B., D'Ambrosio, D. J., Dilling, T. J., Miller, R. C., … Wallner, P. E. (2010). STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: REPORT OF THE ASTRO EMERGING TECHNOLOGY COMMITTEE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(1), 3–10.
- Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT
  Canter, D., Greenberg, R. E., Horwitz, E. M., Kutikov, A., Li, J., Long, C., … Boorjian, S. A. (2010). Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. CANADIAN JOURNAL OF UROLOGY, 17(5), 5365–69.
- PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION: THE CENTRAL ROLE OF TUMOR STAGE AND RADIATION DOSE
  Williams, S., Buyyounouski, M., Kestin, L., Duchesne, G., & Pickles, T. (2011). PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION: THE CENTRAL ROLE OF TUMOR STAGE AND RADIATION DOSE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 79(3), 724–731.
- INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
  Sharma, N. K., Li, T., Chen, D. Y., Pollack, A., Horwitz, E. M., & Buyyounouski, M. K. (2011). INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 80(2), 437–44.
- Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer
  Boorjian, S. A., Karnes, R. J., Viterbo, R., Rangel, L. J., Bergstralh, E. J., Horwitz, E. M., … Buyyounouski, M. K. (2011). Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer. CANCER, 117(13), 2883–2891.
- Androgen Deprivation Therapy in High-Risk Prostate Cancer
  Buyyounouski, M. K. (2010). Androgen Deprivation Therapy in High-Risk Prostate Cancer. ONCOLOGY-NEW YORK, 24(9), 806–9.
- Final report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) for lung tumors
  Feigenberg, S. J., Sharma, N., Yu, J. Q., Buyyounouski, M., Borghaei, H., Scott, W., … Movsas, B. (2009). Final report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) for lung tumors. JOURNAL OF THORACIC ONCOLOGY, 4(9), S943–S943.
- Optimal PET response following stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) is closely related to the pre-SBRT maximum standard uptake value
  Feigenberg, S. J., Sharma, N., Yu Jian Q, J. Q., Lally, B., Borghaei, H., Mehra, R., … Movsas, B. (2009). Optimal PET response following stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) is closely related to the pre-SBRT maximum standard uptake value. JOURNAL OF THORACIC ONCOLOGY, 4(9), S734–S734.
- Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio and biochemical failure in patients with localized prostate cancer: Long-term results
  Turaka, A., Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Greenberg, R. E., & Movsas, B. (2009). Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio and biochemical failure in patients with localized prostate cancer: Long-term results. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
- Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combination with Androgen Deprivation Therapy: The Fox Chase Experience
  Sopka, D. M., Li, T., Horwitz, E. M., Chen, D. Y. T., & Buyyounouski, M. K. (2010). Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combination with Androgen Deprivation Therapy: The Fox Chase Experience. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S351–S352.
- Conventional versus Hypofractionated IMRT: Results of Late GI and GU Toxicity and Quality of Life from a Phase III Trial
  Turaka, A., Zhu, F., Buyyounouski, M. K., Horwitz, E. M., Watkins-Bruner, D., Konski, A. A., & Pollack, A. (2010). Conventional versus Hypofractionated IMRT: Results of Late GI and GU Toxicity and Quality of Life from a Phase III Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S67–S67.
- Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose External Beam Radiation Therapy Prostate Cancer
  Klayton, T. L., Ruth, K., Horwitz, E. M., Uzzo, R. G., Kuritzky, N. K., Chen, D. Y. T., & Buyyounouski, M. K. (2010). Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose External Beam Radiation Therapy Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S334–S334.
- The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience
  Horwitz, E. M., Sharma, N. K., Ruth, K., Silverman, J. S., Buyyounouski, M. K., Chen, D. Y. T., … Uzzo, R. G. (2010). The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S333–S334.
- Interval to Biochemical Failure is Highly Prognostic for Distant Metastases and Mortality after Salvage Radiation Therapy
  Buyyounouski, M. K., Li, T., Turaka, A., Chen, D. Y. T., & Horwitz, E. M. (2010). Interval to Biochemical Failure is Highly Prognostic for Distant Metastases and Mortality after Salvage Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S348–S348.
- Improved V20 and V30 and Faster Treatment Time with Arc Compared to Fixed Beam IMRT for Stage III NSCLC
  Li, L., Buyyounouski, M. K., Cherian, G., Wang, L., Ma, C., & Price, R. (2010). Improved V20 and V30 and Faster Treatment Time with Arc Compared to Fixed Beam IMRT for Stage III NSCLC. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. SAN DIEGO,CA,CA: ELSEVIER SCIENCE INC.
- A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System
  Li, J., Jin, L., Horwitz, E. M., Buyyounouski, M. K., Price, R. A., & Ma, C. (2010). A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S701–S702.
- The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT
  Keller, L. M., Ruth, K., Horwitz, E. M., Pollack, A., Watkins-Bruner, D., Konski, A., … Buyyounouski, M. K. (2010). The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S596–S597.
- Low Pretreatment PET SUV Predicts for Increased Local Failure following Stereotactic Body Radiation Therapy for Lung Cancer
  Husain, Z. A., Sharma, N. K., Hanlon, A. L., Buyyounouski, M. K., Mirmiran, A., Dhople, A. A., … Feigenberg, S. J. (2010). Low Pretreatment PET SUV Predicts for Increased Local Failure following Stereotactic Body Radiation Therapy for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S525–S525.
- Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy
  Zietman, A. L., HUNT, D., Kaufman, D. S., Uzzo, R., Wu, C., Buyyounouski, M. K., … Shipley, W. U. (2010). Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S31–S32.
- RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER
  Lawton, C. A. F., Michalski, J., El-Naqa, I., Buyyounouski, M. K., Lee, W. R., Menard, C., … Seider, M. (2009). RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 74(2), 383–387.
- Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: Evaluation of the impact on daily dose coverage
  Wang, L., Hayes, S., Paskalev, K., Jin, L., Buyyounouski, M. K., Ma, C. C. M., & Feigenberg, S. (2009). Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: Evaluation of the impact on daily dose coverage. RADIOTHERAPY AND ONCOLOGY, 91(3), 314–24.
- Androgen Deprivation Therapy and Prostate Cancer Duration
  Williams, S. G., Pickles, T., & Buyyounouski, M. K. (2009). Androgen Deprivation Therapy and Prostate Cancer Duration. JOURNAL OF CLINICAL ONCOLOGY, 27(34), E228–E228.
- GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERNAL BEAM RADIATION THERAPY
  Li, J. S., Jin, L., Pollack, A., Horwitz, E. M., Buyyounouski, M. K., Price, R. A., & Ma, C.-M. (2009). GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERNAL BEAM RADIATION THERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(5), 1613–20.
- Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population
  Kaplan, D. J., Boorjian, S. A., Ruth, K., Egleston, B. L., Chen, D. Y. T., Viterbo, R., … Giri, V. N. (2010). Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU INTERNATIONAL, 105(3), 334–37.
- DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR POSTOPERATIVE CONFORMAL RADIATION THERAPY FOR PROSTATE CANCER
  Michalski, J. M., Lawton, C., El Naqa, I., Ritter, M., O'Meara, E., Seider, M. J., … Menard, C. (2010). DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR POSTOPERATIVE CONFORMAL RADIATION THERAPY FOR PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76(2), 361–68.
- Surveillance for Stage I Seminoma: Better the Devil You Know Than the Devil You Don't? The Lawrentschuk/Fleshner Article Reviewed
  Buyyounouski, M. K. (2009). Surveillance for Stage I Seminoma: Better the Devil You Know Than the Devil You Don't? The Lawrentschuk/Fleshner Article Reviewed. ONCOLOGY-NEW YORK, 23(9), 762–64.
- Commentary on dose escalation and biochemical failure in prostate cancer: In regard to Eade et al. (Int J Radiat Oncol Biol Phys 2007;68 : 682-689) - In reply
  Pollack, A., Eade, T. N., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., & Hanks, G. E. (2008). Commentary on dose escalation and biochemical failure in prostate cancer: In regard to Eade et al. (Int J Radiat Oncol Biol Phys 2007;68 : 682-689) - In reply. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(2), 645–646.
- Influence of local tumor control on distant metastases and cancer related mortality after external, beam radiotherapy for prostate cancer - Editorial comment
  Buyyounouski, M. K. (2008). Influence of local tumor control on distant metastases and cancer related mortality after external, beam radiotherapy for prostate cancer - Editorial comment. JOURNAL OF UROLOGY, 179(4), 1373–1373.
- Comment on dose escalation and biochemical failure in prostate cancer: In regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70 : 67-74) - In reply to Drs. Schultz and Kagan
  Pollack, A., Eade, T. M., Horwitz, E. M., Buyyounouski, M. K., & Hanks, G. E. (2008). Comment on dose escalation and biochemical failure in prostate cancer: In regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70 : 67-74) - In reply to Drs. Schultz and Kagan. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(4), 1288–1289.
- Predicting local persistence of intermediate and high-risk prostate cancer using percentage of adenocarcinoma in pretreatment biopsy tissue
  Buyyounouski, M. K., Li, T., Al-Saleem, T., Horwitz, E., Konski, A., Feigenberg, S., … Pollack, A. (2008). Predicting local persistence of intermediate and high-risk prostate cancer using percentage of adenocarcinoma in pretreatment biopsy tissue. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S321–S322.
- Residual Prostate Cancer After Radiotherapy: A Study of Radical Cystoprostatectomy Specimens Editorial Comment
  Kaplan, D. J., Crispen, P. L., Greenberg, R. E., Chen, D. Y., Viterbo, R., Buyyounouski, M. K., … Uzzo, R. G. (2009). Residual Prostate Cancer After Radiotherapy: A Study of Radical Cystoprostatectomy Specimens Editorial Comment. JOURNAL OF UROLOGY, 181(5), 2111–2112.
- Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for Low-intermediate Risk Prostate Cancer
  Sharma, N. K., Ruth, K. J., Boorjian, S. A., Uzzo, R. G., Buyyounouski, M. K., & Horwitz, E. M. (2009). Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for Low-intermediate Risk Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S313–S313.
- A Potential Outcomes Framework to Determine Whether Age and Medical Co-morbidities Predict Who is Harmed by Combined Androgen Deprivation Therapy
  Silverman, J. S., Egleston, B., Horwitz, E. M., Chen, D. Y. T., & Buyyounouski, M. K. (2009). A Potential Outcomes Framework to Determine Whether Age and Medical Co-morbidities Predict Who is Harmed by Combined Androgen Deprivation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S326–S326.
- Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer
  Buyyounouski, M. K., Pickles, T., Kestin, L., Allison, R., & Williams, S. G. (2009). Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S103–S104.
- Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial
  Pollack, A., Li, T., Buyyounouski, M., Horwitz, E., Price, R., Feigenberg, S., … Ma, C. (2009). Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S81–S82.
- Defining Biochemical Failure following Salvage Radiotherapy
  Lubbe, W. J., Ruth, K., Devarajan, K., Horwitz, E. M., Boorjian, S., & Buyyounouski, M. K. (2009). Defining Biochemical Failure following Salvage Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S330–S330.
- Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy?
  Cohen, R. J., Sharma, N. K., Ruth, K., Buyyounouski, M. K., Li, J., Crawford, K., … Horwitz, E. M. (2009). Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S298–S298.
- Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate Risk Prostate Cancer is an Independent Predictor of Biochemical and Clinical Outcome
  Horwitz, E. M., Ruth, K. J., Sharma, N. K., Chen, D. Y. T., Buyyounouski, M. K., & Uzzo, R. G. (2009). Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate Risk Prostate Cancer is an Independent Predictor of Biochemical and Clinical Outcome. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S301–S301.
- The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer
  Abramowitz, M. C., Li, T., Buyyounouski, M. K., Ross, E., Uzzo, R. G., Pollack, A., & Horwitz, E. M. (2008). The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. CANCER, 112(1), 55–60.
- Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance
  Williams, S. G., Buyyounouski, M. K., Pickles, T., Kestin, L., Martinez, A., Hanlon, A. L., & Duchesne, G. M. (2008). Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(4), 1169–1175.
- How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
  D'Ambrosio, D. J., Ruth, K., Horwitz, E. M., Uzzo, R. G., Pollack, A., & Buyyounouski, M. K. (2008). How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(5), 1487–91.
- Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
  D'Ambrosio, D. J., Ruth, K., Horwitz, E. M., Chen, D. Y. T., Pollack, A., & Buyyounouski, M. K. (2008). Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer? UROLOGY, 71(5), 938–41.
- A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or I-125 permanent implant
  Eade, T. N., Horwitz, E. M., Ruth, K., Buyyounouski, M. K., D'Ambrosio, D. J., Feigenberg, S. J., … Pollack, A. (2008). A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or I-125 permanent implant. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(2), 338–45.
- Residual prostate cancer after radiotherapy: A study of radical cystoprostatectomy specimens
  Kaplan, D. J., Crispen, P. L., Greenberg, R. E., Chen, D. Y. T., Viterbo, R., Buyyounouski, M. K., … Uzzo, R. G. (2008). Residual prostate cancer after radiotherapy: A study of radical cystoprostatectomy specimens. UROLOGY, 72(3), 654–58.
- DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER?
  D'Ambrosio, D. J., Li, T., Horwitz, E. M., Chen, D. Y. T., Pollack, A., & Buyyounouski, M. K. (2008). DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(5), 1402–7.
- Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men
  Giri, V. N., Egleston, B., Ruth, K., Uzzo, R. G., Chen, D. Y. T., Buyyounouski, M., … Kittles, R. (2009). Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men. CANCER PREVENTION RESEARCH, 2(3), 244–50.
- Daily localization for prostate bed patients based on surgical clips
  Paskalev, K., Horwitz, E., Price, R., Feigenberg, S., Buyyounouski, M., Chen, Y., … Pollack, A. (2007). Daily localization for prostate bed patients based on surgical clips. MEDICAL PHYSICS, 34(6), 2381–2382.
- Do stranded seeds improve the quality of permanent prostate seed implant?
  Li, J., Horwitz, E., Buyyounouski, M., McNeeley, S., Crawford, K., & Ma, C. (2007). Do stranded seeds improve the quality of permanent prostate seed implant? MEDICAL PHYSICS, 34(6), 2330–2330.
- Surface smoothing of a tubular structure using a non-shrinking algorithm
  Chen, Y., Paskalev, K., Horwitz, E., Price, R., Buyyounouski, M., Ma, C., & Pollack, A. (2007). Surface smoothing of a tubular structure using a non-shrinking algorithm. MEDICAL PHYSICS, 34(6), 2637–2637.
- Phase I dose escalation trial of image guided stereotactic body radiotherapy for lung tumors
  Feigenberg, S. J., Sharma, N., Wang, L., Cohen, R., Buyyounouski, M., Lally, B., & Movsas, B. (2008). Phase I dose escalation trial of image guided stereotactic body radiotherapy for lung tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. BOSTON,MA,MA: ELSEVIER SCIENCE INC.
- The optimum duration of combination androgen deprivation therapy (ADT) with prostate cancer radiotherapy: Determining the duration-benefit relationship from multi-institutional analysis
  Pickles, T., Williams, S. G., Buyyounouski, M. K., Kestin, L. L., & Duchesne, G. M. (2008). The optimum duration of combination androgen deprivation therapy (ADT) with prostate cancer radiotherapy: Determining the duration-benefit relationship from multi-institutional analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S73–S73.
- The effect of race on combining surgery and radiation in locally advanced non-small cell lung cancer
  Lally, B. E., Blackstock, A., Buyyounouski, M. K., Feigenberg, S. J., Scott, W. J., Thomas, C. R., & Konski, A. A. (2008). The effect of race on combining surgery and radiation in locally advanced non-small cell lung cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. BOSTON,MA,MA: ELSEVIER SCIENCE INC.
- Estimating gains in biochemical outcome from various durations of androgen deprivation in patients treated with dose escalated radiotherapy for prostate cancer using two nomograms
  Pahlajani, N. H., Egleston, B. L., Buyyounouski, M. K., Chen, D. Y. T., Horwitz, E., & Pollack, A. (2008). Estimating gains in biochemical outcome from various durations of androgen deprivation in patients treated with dose escalated radiotherapy for prostate cancer using two nomograms. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S54–S54.
- Radiation therapy for high risk prostate cancer: Do patients 70 years or older benefit from combined androgen deprivation therapy?
  Silverman, J. S., Ruth, K., Horwitz, E. M., Pollack, A., Chen, D. Y. T., & Buyyounouski, M. K. (2008). Radiation therapy for high risk prostate cancer: Do patients 70 years or older benefit from combined androgen deprivation therapy? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S75–S76.
- Androgen deprivation therapy plus hypofractionated prostate radiotherapy-are we castrating the radiobiological advantage?
  Williams, S. G., Pickles, T., Kestin, L., Buyyounouski, M., Martinez, A., Demanes, J., … Duchesne, G. (2008). Androgen deprivation therapy plus hypofractionated prostate radiotherapy-are we castrating the radiobiological advantage? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S73–S74.
- Low morbidity and excellent local control using image guided stereotactic body radiotherapy (IGSBRT) for lung tumors
  Sharma, N. K., Ruth, K., Konski, A. A., Buyyounouski, M. K., Nicolaou, N., Lally, B. E., … Feigenberg, S. J. (2008). Low morbidity and excellent local control using image guided stereotactic body radiotherapy (IGSBRT) for lung tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S454–S454.
- Gains from real-time prostate motion monitoring during external beam radiation therapy
  Li, J., Jin, L., Horwitz, E., Buyyounouski, M., Pollack, A., Johnston, S., … Ma, C. (2008). Gains from real-time prostate motion monitoring during external beam radiation therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S287–S288.
- PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT or IMRT using the Phoenix definition
  Horwitz, E. M., Ruth, K., Uzzo, R. G., Buyyounouski, M. K., Wong, Y., Chen, D. Y. T., & Pollack, A. (2008). PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT or IMRT using the Phoenix definition. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S135–S136.
- Radiation dose and late failures in prostate cancer
  Morgan, P. B., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2007). Radiation dose and late failures in prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 67(4), 1074–81.
- Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate
  Eade, T. N., Al-Saleem, T., Horwitz, E. M., Buyyounouski, M. K., Chen, D. Y. T., & Pollack, A. (2007). Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. CANCER, 109(10), 2011–15.
- Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
  Morgan, P. B., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2007). Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. CANCER, 110(1), 68–80.
- What dose of external-beam radiation is high enough for prostate cancer?
  Eade, T. N., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Hanks, G. E., & Pollack, A. (2007). What dose of external-beam radiation is high enough for prostate cancer? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 68(3), 682–89.
- Prostate cancer risk assessment program: A 10-year update of cancer detection
  Giri, V. N., Beebe-Dimmer, J., Buyyounouski, M., Konski, A., Feigenberg, S. J., Uzzo, R. G., … Watkins-Bruner, D. (2007). Prostate cancer risk assessment program: A 10-year update of cancer detection. JOURNAL OF UROLOGY, 178(5), 1920–24.
- Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
  Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., & Pollack, A. (2008). Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(1), 59–66.
- Adjusted radiotherapy dose response curves following treatment for prostate cancer: Biochemical failure and distant metastasis
  Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., & Pollack, A. (2006). Adjusted radiotherapy dose response curves following treatment for prostate cancer: Biochemical failure and distant metastasis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S346–S347.
- The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: Distant metastasis are the cause
  Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., & Pollack, A. (2006). The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: Distant metastasis are the cause. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S206–S207.
- CT-based daily localization of prostate patients: Anatomy vs. implanted markers
  Paskalev, K., Feigenberg, S., McNeeley, S., Horwitz, E., Price, R., Konski, A., … Alan, P. (2006). CT-based daily localization of prostate patients: Anatomy vs. implanted markers. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S621–S621.
- Prostate specific antigen kinetics in men treated with radiotherapy and androgen deprivation
  D'Ambrosio, D. J., Ruth, K., Buyyounouski, M. K., Horwitz, E. M., Uzzo, R. G., & Pollack, A. (2006). Prostate specific antigen kinetics in men treated with radiotherapy and androgen deprivation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S334–S334.
- Intensity modulated radiation therapy for prostate cancer: Preliminary results on treatment morbidity compared to 3-D conformal radiation therapy
  Kirichenko, A. V., Ruth, K., Horwitz, E. M., Buyyounouski, M. K., Feigenberg, S. J., Chen, D. Y., & Pollack, A. (2006). Intensity modulated radiation therapy for prostate cancer: Preliminary results on treatment morbidity compared to 3-D conformal radiation therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S326–S326.
- The nadir+2 definition of biochemical failure predicts for overall survival
  Abramowitz, M. C., Li, T., Ross, E., Buyyounouski, M., Uzzo, R. G., Pollack, A., & Horwitz, E. M. (2006). The nadir+2 definition of biochemical failure predicts for overall survival. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S207–S208.
- Comparison of outcomes in low risk prostate cancer: I-125 seed brachytherapy vs. intensity modulated radiotherapy
  Eade, T. N., Ruth, K., D'Ambrosio, D. J., Feigenberg, S. J., Buyyounouski, M. K., Uzzo, R. G., … Horwitz, E. M. (2006). Comparison of outcomes in low risk prostate cancer: I-125 seed brachytherapy vs. intensity modulated radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S60–S61.
- Smoking and its relationship to GU and GI toxicity in prostate cancer patients treated with radiation
  Pahlajani, N. H., Ruth, K., Horwitz, E. M., Buyyounouski, M. B., Chen, D. Y., & Pollack, A. (2006). Smoking and its relationship to GU and GI toxicity in prostate cancer patients treated with radiation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S317–S317.
- Increasing radiotherapy dose for prostate cancer reduces a late wave of distant metastasis
  Morgan, P. B., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2006). Increasing radiotherapy dose for prostate cancer reduces a late wave of distant metastasis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S9–S10.
- Daily changes in seminal vesicle location during treatment of prostate carcinoma
  McNeeley, S., Paskalev, K., Buyyounouski, M., & Ma, C. (2006). Daily changes in seminal vesicle location during treatment of prostate carcinoma. MEDICAL PHYSICS, 33(6), 2030–2030.
- FDG PET response by 3 months following stereotactic body radiotherapy for non-small cell lung cancer may be an early surrogate of local failure
  Feigenberg, S., Yu, J. Q. M., Eade, T. N., Buyyounouski, M., Wang, L., Langer, C., … Movsas, B. (2007). FDG PET response by 3 months following stereotactic body radiotherapy for non-small cell lung cancer may be an early surrogate of local failure. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S479–S480.
- Effect of target smoothness on treatment planning for prostate IMRT
  Chen, Y., Paskalev, K., Horwitz, E., Price, R., Buyyounouski, M., Ma, C., & Pollack, A. (2007). Effect of target smoothness on treatment planning for prostate IMRT. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S649–S649.
- Does total treatment duration affect outcome in prostate cancer treated with radiotherapy?
  D'Ambrosio, D. J., Horwitz, T. L. E. M., Chen, D., Pollack, A., & Buyyounouski, M. K. (2007). Does total treatment duration affect outcome in prostate cancer treated with radiotherapy? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S176–S176.
- Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer
  Sharma, N. K., Li, T., Horwitz, E. M., Pollack, A., & Buyyounouski, M. K. (2007). Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S10–S10.
- A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: Toxicity and outcomes
  Morgan, P. B., Ruth, K., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2007). A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: Toxicity and outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S319–S319.
- A comparison of sexual function following radiotherapy for prostate cancer: Results of a prospective, randomized trial of hypofractionated intensity modulated radiotherapy
  Buyyounouski, M. K., Li, T., Watkins-Bruner, D., Horwitz, E. M., & Pollack, A. (2007). A comparison of sexual function following radiotherapy for prostate cancer: Results of a prospective, randomized trial of hypofractionated intensity modulated radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S7–S8.
- Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death
  Alcantara, P., Hanlon, A., Buyyounouski, M. K., Horwitz, E. M., & Pollack, A. (2007). Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. CANCER, 109(1), 41–47.
- The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
  D'Ambrosio, D. J., Hanlon, A. L., Al-Saleem, T., Feigenberg, S. J., Horwitz, E. M., Uzzo, R. G., … Buyyounouski, M. K. (2007). The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 67(4), 1082–87.
- Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
  Pollack, A., Hanlon, A. L., Horwitz, E. M., Feigenberg, S. J., Konski, A. A., Movsas, B., … Price, R. A. (2006). Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 64(2), 518–26.
- Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer
  Price, R. A., Hannoun-Levi, J.-M., Horvvitz, E., Buyyounouski, M., Ruth, K. J., Ma, C.-M., & Pollack, A. (2006). Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(2), 583–92.
- Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
  Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Uzzo, R. G., & Pollack, A. (2005). Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 61(5), 1291–98.
- The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
  Buyyounouski, M. K., Horwitz, E. M., Uzzo, R. G., Price, R. A., McNeeley, S. W., Azizi, D., … Pollack, A. (2004). The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 59(5), 1383–91.
- In reply to Cheung.
  Turaka, A., Buyyounouski, M. K., Horwitz, E. M., & Movsas, B. (2013). In reply to Cheung. International Journal of Radiation Oncology, Biology, Physics, 86(1), 6–7.
- Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.
  Pollack, A., Walker, G., Horwitz, E. M., Price, R., Feigenberg, S., Konski, A. A., … Buyyounouski, M. K. (2013). Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. Journal of Clinical Oncology , 31(31), 3860–68.
- Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment
  Buyyounouski, M. K., Horwitz, E. M., Price, R. A., Hanlon, A. L., Uzzo, R. G., & Pollack, A. (2004). Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(3), 743–49.
- Positive prostate biopsy laterality and implications for staging
  Buyyounouski, M. K., Horwitz, E. M., Hanlon, A. L., Uzzo, R. G., Hanks, G. E., & Pollack, A. (2003). Positive prostate biopsy laterality and implications for staging. UROLOGY, 62(2), 298–303.
- Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database.
  Buyyounouski, M. K., Horwitz, E. M., Hanlon, A. L., Uzzo, R. G., & Pollack, A. (2004). Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database. Journal of Urology, 171(3), 1246–1247.
- Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
  Buyyounouski, M. K., Hanlon, A. L., Eisenberg, D. F., Horwitz, E. M., Feigenberg, S. J., Uzzo, R. G., & Pollack, A. (2005). Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(5), 1455–62.
- Radiation therapy for pituitary metastasis: report of four cases.
  Turaka, A., Parsons, R. B., & Buyyounouski, M. K. (2012). Radiation therapy for pituitary metastasis: report of four cases. Tumori, 98(1), e1–6.
- In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046.
  Buyyounouski, M. K., Hanlon, A. L., Price, R. A., Horwitz, E. M., Feigenberg, S. J., & Pollack, A. (2004). In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046. International Journal of Radiation Oncology, Biology, Physics, 60(5), 1664–1665.
- Does family history of prostate cancer affect outcomes following radiotherapy?
  Bagshaw, H., Ruth, K., Horwitz, E. M., Chen, D. Y. T., & Buyyounouski, M. K. (2014). Does family history of prostate cancer affect outcomes following radiotherapy? Radiotherapy and Oncology , 110(2), 229–34.
- Reply to m.j. Brenner et Al and I.R. Vogelius et Al.
  Pollack, A., Walker, G., Horwitz, E. M., Price, R., Feigenberg, S., Konski, A. A., … Buyyounouski, M. K. (2014). Reply to m.j. Brenner et Al and I.R. Vogelius et Al. Journal of Clinical Oncology , 32(17), 1853–54.
- Salvage low-dose-rate I-125 partial prostate brachytherapy after dose-escalated external beam radiotherapy
  Chang, L., & Buyyounouski, M. K. (2014). Salvage low-dose-rate I-125 partial prostate brachytherapy after dose-escalated external beam radiotherapy. JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 6(3), 304–10.
- Prostate cancer gene therapy and the role of radiation
  Kaminski, J. M., Nguyen, K., Buyyounouski, M., & Pollack, A. (2002). Prostate cancer gene therapy and the role of radiation. CANCER TREATMENT REVIEWS, 28(1), 49–64.
- Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial
  Pisansky, T. M., Pugh, S. L., Greenberg, R. E., Pervez, N., Reed, D. R., Rosenthal, S. A., … Bruner, D. W. (2014). Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 311(13), 1300–1307.
- Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled
  Huang, K. T., Stoyanova, R., Walker, G., Sandler, K., Studenski, M. T., Dogan, N., … Pollack, A. (2015). Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. RADIOTHERAPY AND ONCOLOGY, 115(1), 101–6.
- Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques.
  Murphy, C. T., Heller, S., Ruth, K., Buyyounouski, M. K., Weinberg, D., Uzzo, R. G., … Horwitz, E. M. (2015). Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Practical Radiation Oncology, 5(3), e215–22.
- Seminal Vesicle Target Delineation for Intermediate-Risk Prostate Cancer IMRT.
  Johnson, M. E., Ruth, K., Buyyounouski, M. K., & Horwitz, E. M. (2013). Seminal Vesicle Target Delineation for Intermediate-Risk Prostate Cancer IMRT. Practical Radiation Oncology, 3(2), S31–2.
- Continuous localization technologies for radiotherapy delivery: Report of the American Society for Radiation Oncology Emerging Technology Committee.
  D'Ambrosio, D. J., Bayouth, J., Chetty, I. J., Buyyounouski, M. K., Price, R. A., Correa, C. R., … Konski, A. (2012). Continuous localization technologies for radiotherapy delivery: Report of the American Society for Radiation Oncology Emerging Technology Committee. Practical Radiation Oncology, 2(2), 145–50.
- Development and preliminary testing of PROGRESS: a Web-based education program for prostate cancer survivors transitioning from active treatment
  Miller, S. M., Hudson, S. V., Hui, S.-kuen A., Diefenbach, M. A., Fleisher, L., Raivitch, S., … Baman, J. (2015). Development and preliminary testing of PROGRESS: a Web-based education program for prostate cancer survivors transitioning from active treatment. JOURNAL OF CANCER SURVIVORSHIP, 9(3), 541–53.
- Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer.
  Martin, J. M., Handorf, E. A., Price, R. A., Cherian, G., Buyyounouski, M. K., Chen, D. Y., … Horwitz, E. M. (2015). Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. Medical Dosimetry , 40(3), 186–89.
- Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer
  Martin, J. M., Handorf, E. A., Price, R. A., Cherian, G., Buyyounouski, M. K., Chen, D. Y., … Horwitz, E. M. (2015). Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. MEDICAL DOSIMETRY, 40(3), 186–89.
- Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?
  Barbosa, P. V., Thomas, I.-C., Srinivas, S., Buyyounouski, M. K., Chung, B. I., Chertow, G. M., … Leppert, J. T. (2016). Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable? EUROPEAN UROLOGY, 70(2), 227–30.
- Electronic Release of Pathology and Radiology Results to Patients: Opinions and Experiences of Oncologists.
  Winget, M., Haji-Sheikhi, F., Brown-Johnson, C., Rosenthal, E. L., Sharp, C., Buyyounouski, M. K., & Asch, S. M. (2016). Electronic Release of Pathology and Radiology Results to Patients: Opinions and Experiences of Oncologists. Journal of Oncology Practice / American Society of Clinical Oncology, 12(8), e792–9.
- NCCN Guidelines (R) Insights Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines
  Clark, P. E., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., … Smith, C. (2016). NCCN Guidelines (R) Insights Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(10), 1213–24.
- Androgen deprivation therapy toxicity and management for men receiving radiation therapy.
  Johnson, M. E., & Buyyounouski, M. K. (2012). Androgen deprivation therapy toxicity and management for men receiving radiation therapy. Prostate Cancer, 2012, 580306-?
- Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer.
  Sharma, N. K., Li, T., Chen, D. Y., Pollack, A., Horwitz, E. M., & Buyyounouski, M. K. (2007). Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 69(3), S10-?
- NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.
  Clark, P. E., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., … Smith, C. (2016). NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network , 14(10), 1213–24.
- SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
  Kishan, A. U., Wang, P.-C., Upadhyaya, S. K., Hauswald, H., Demanes, D. J., Nickols, N. G., … King, C. R. (2016). SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Practical Radiation Oncology, 6(4), 268–75.
- Robust Estimation of Electron Density From Anatomic Magnetic Resonance Imaging of the Brain Using a Unifying Multi-Atlas Approach.
  Ren, S., Hara, W., Wang, L., Buyyounouski, M. K., Le, Q.-T., Xing, L., & Li, R. (2017). Robust Estimation of Electron Density From Anatomic Magnetic Resonance Imaging of the Brain Using a Unifying Multi-Atlas Approach. International Journal of Radiation Oncology, Biology, Physics, 97(4), 849–57.
- Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
  Buyyounouski, M. K., Choyke, P. L., McKenney, J. K., Sartor, O., Sandler, H. M., Amin, M. B., … Lin, D. W. (2017). Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a Cancer Journal for Clinicians.
- Prostate Cancer - Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
  Buyyounouski, M. K., Choyke, P. L., McKenney, J. K., Sartor, O., Sandler, H. M., Amin, M. B., … Lin, D. W. (2017). Prostate Cancer - Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA-A CANCER JOURNAL FOR CLINICIANS, 67(3), 246–53.
- Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer
  Pollack, A., Kwon, D., Walker, G., Khor, L. Y., Horwitz, E. M., Buyyounouski, M. K., & Stoyanova, R. (2017). Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 109(2).
- Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center
  Porter, J. B. (2017). Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center, 13(8), e673–e682.
- Oncologists' opinions and experiences with electronic release of radiology and pathology results to patients.
  Winget, M., Sheikhi, F., Rosenthal, E. L., Sharp, C., Buyyounouski, M. K., & Asch, S. (2016). Oncologists' opinions and experiences with electronic release of radiology and pathology results to patients. JOURNAL OF CLINICAL ONCOLOGY, 34(7).
- Peering over the chasm: Diffusion of prostate radiation therapy hypofractionation
  Buyyounouski, M. K. (2017). Peering over the chasm: Diffusion of prostate radiation therapy hypofractionation. PRACTICAL RADIATION ONCOLOGY, 7(4), 279–80.
- What More Can Be Learned From the ASCENDE-RT Trial?
  Hamstra, D. A., Krauss, D., & Buyyounouski, M. K. (2017). What More Can Be Learned From the ASCENDE-RT Trial? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(2), 481–82.
- Aspirin use decreases the risk of prostate cancer recurrence after post-prostatectomy radiotherapy
  Zaorsky, N. G., Li, T., Cohen, R. J., Horwitz, E. M., Uzzo, R. G., Viterbo, R., & Buyyounouski, M. K. (2015). Aspirin use decreases the risk of prostate cancer recurrence after post-prostatectomy radiotherapy. JOURNAL OF RADIATION ONCOLOGY, 4(2), 193–201.
- The Case for Prostate Brachytherapy in the Affordable Care Act Era
  Durkee, B. Y., & Buyyounouski, M. K. (2015). The Case for Prostate Brachytherapy in the Affordable Care Act Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 91(3), 465–67.
- Toxicity analysis of lymph node irradiation for prostate cancer patients treated with IMRT
  Johnson, M. E., Li, T., Kutikov, A., Buyyounouski, M. K., Sobczak, M. L., Viterbo, R., & Horwitz, E. M. (2014). Toxicity analysis of lymph node irradiation for prostate cancer patients treated with IMRT. JOURNAL OF CLINICAL ONCOLOGY, 32(4).
- Interval to biochemical failure is prognostic for distant metastases after salvage radiation therapy for prostate cancer
  Zaorsky, N. G., Li, T., Turaka, A., Chen, D. Y. T., Horwitz, E. M., & Buyyounouski, M. K. (2016). Interval to biochemical failure is prognostic for distant metastases after salvage radiation therapy for prostate cancer. JOURNAL OF RADIATION ONCOLOGY, 5(1), 79–85.
- Assessment of the American Joint Committee on Cancer (6th and 7th editions) for clinically localized prostate cancer and comparison to the National Comprehensive Cancer Network risk stratification method
  Buyyounouski, M. K., Zaorsky, N. G., Li, T., Devarajan, K., & Horwitz, E. M. (2012). Assessment of the American Joint Committee on Cancer (6th and 7th editions) for clinically localized prostate cancer and comparison to the National Comprehensive Cancer Network risk stratification method. JOURNAL OF CLINICAL ONCOLOGY, 30(5).
- Examining the evidence in pursuit of the highest possible brachytherapy standards
  Buyyounouski, M. K., Viswanathan, A. N., & Prestidge, B. R. (2014). Examining the evidence in pursuit of the highest possible brachytherapy standards. BRACHYTHERAPY, 13(1), 15–16.
- Preliminary results of RTOG 0831, a randomized, double-blinded, placebo-controlled trial of tadalafil in the prevention of erectile dysfunction in patients treated with radiotherapy for prostate cancer
  Bruner, D., Pugh, S. L., Pisansky, T. M., Greenberg, R. E., Pervez, N., Reed, D. R., … Kachnic, L. A. (2013). Preliminary results of RTOG 0831, a randomized, double-blinded, placebo-controlled trial of tadalafil in the prevention of erectile dysfunction in patients treated with radiotherapy for prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(15).
- Radiobiological Modeling and the Study of Hypofractionated Radiotherapy for Prostate Cancer
  Buyyounouski, M. K. (2014). Radiobiological Modeling and the Study of Hypofractionated Radiotherapy for Prostate Cancer. EUROPEAN UROLOGY, 66(6), 1031–32.
- A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704
  Heestand, G. M., Murphy, J. D., Moughan, J., Regine, W., Luo, J., Graber, M. S., … Koong, A. (2014). A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Bladder Cancer, Version 5.2017
  Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Clark, P. E., … Gurski, L. A. (2017). Bladder Cancer, Version 5.2017. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(10), 1240–67.
- RTOG 0320:A phase Ill trial comparing whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone versus WBRT with temozolomide (TMZ) or erlotinib for non-small cell lung cancer (NSCLC) and 1-3 brain metastases
  Sperduto, P. W., Wang, M., Robins, H. I., Schell, M. C., Werner-Wasik, M., Komaki, R. U., … Mehta, M. P. (2012). RTOG 0320:A phase Ill trial comparing whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone versus WBRT with temozolomide (TMZ) or erlotinib for non-small cell lung cancer (NSCLC) and 1-3 brain metastases. CANCER RESEARCH, 72.
- Use of biopsy detail to identify subgroup risk in high-risk patients with prostate cancer
  Townsend, N. C., Buyyounouski, M. K., Ruth, K. J., Kutikov, A., Viterbo, R., Sobczak, M., … Horwitz, E. M. (2013). Use of biopsy detail to identify subgroup risk in high-risk patients with prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(6).
- Radiation therapy for prostate cancer
  Buyyounouski, M. K. (2018). Radiation therapy for prostate cancer. TRANSLATIONAL ANDROLOGY AND UROLOGY, 7(3), 295–96.
- NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
  Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., … Gurski, L. A. (2018). NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network : JNCCN, 16(9), 1041–53.
- Lung cancer presents as Addisonian crisis secondary to a solitary pituitary metastasis
  Turaka, A., Parsons, R. B., & Buyyounouski, M. K. (2009). Lung cancer presents as Addisonian crisis secondary to a solitary pituitary metastasis. JOURNAL OF RADIOTHERAPY IN PRACTICE, 8(4), 229–32.
- Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
  Morgan, S. C., Hoffman, K., Loblaw, D. A., Buyyounouski, M. K., Patton, C., Barocas, D., … Sandler, H. (2018). Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801097.
- Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
  Morgan, S. C., Hoffman, K., Loblaw, D. A., Buyyounouski, M. K., Patton, C., Barocas, D., … Sandler, H. (2018). Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. The Journal of Urology.
- Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.
  Morgan, S. C., Hoffman, K., Loblaw, D. A., Buyyounouski, M. K., Patton, C., Barocas, D., … Sandler, H. (2018). Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Practical Radiation Oncology, 8(6), 354–60.
- Dosimetric Features-Driven Machine Learning Model for DVHs Prediction in VMAT Treatment Planning.
  Ma, M., Kovalchuk, N., Buyyounouski, M. K., Xing, L., & Yang, Y. (2018). Dosimetric Features-Driven Machine Learning Model for DVHs Prediction in VMAT Treatment Planning. Medical Physics.
- Prostate Cancer Classification with Multi-parametric MRI Transfer Learning Model.
  Yuan, Y., Qin, W., Buyyounouski, M., Ibragimov, B., Hancock, S., Han, B., & Xing, L. (2018). Prostate Cancer Classification with Multi-parametric MRI Transfer Learning Model. Medical Physics.
- Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.
  Kishan, A. U., Dang, A., Katz, A. J., Mantz, C. A., Collins, S. P., Aghdam, N., … King, C. R. (2019). Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Network Open, 2(2), e188006.
- Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
  Morgan, S. C., Hoffman, K., Loblaw, D. A., Buyyounouski, M. K., Patton, C., Barocas, D., … Sandler, H. (2019). Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. The Journal of Urology, 201(3), 528–34.
- Evaluating Prostate-Specific Antigen (PSA) Nadir and Bounce After Stereotactic Body Radiotherapy (SBRT) in a Multi-Institutional Cohort
  Jiang, N., Dang, A., Yuan, Y., Chu, F.-I., King, C., Collins, S., … Kishan, A. (2019). Evaluating Prostate-Specific Antigen (PSA) Nadir and Bounce After Stereotactic Body Radiotherapy (SBRT) in a Multi-Institutional Cohort. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 103(5), E17.
- Long-term outcomes of stereotactic body radiotherapy for low- and intermediate-risk prostate adenocarcinoma: A multi-institutional consortium study.
  Kishan, A. U., Katz, A. J., Mantz, C., Chu, F.-, Appelbaum, L., Loblaw, A., … King, C. R. (2018). Long-term outcomes of stereotactic body radiotherapy for low- and intermediate-risk prostate adenocarcinoma: A multi-institutional consortium study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- FDG PET imaging of signet-ring cell adenocarcinoma of the stomach
  Buyyounouski, M. K., Klump, W. J., Konski, A., Wu, H., & Adler, L. P. (2005). FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. CLINICAL NUCLEAR MEDICINE, 30(2), 118–19.
- Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition
  Klayton, T. L., Ruth, K., Buyyounouski, M. K., Uzzo, R. G., Wong, Y.-N., Chen, D. Y. T., … Horwitz, E. M. (2011). Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition. PRACTICAL RADIATION ONCOLOGY, 1(4), 235–42.
- Radiation therapy for prostate cancer.
  Buyyounouski, M. K. (2018). Radiation therapy for prostate cancer. Translational Andrology and Urology, 7(3), 295–296.
- Prostate cancer: stratifying intermediate-risk patients for radiotherapy.
  Buyyounouski, M. K. (2013). Prostate cancer: stratifying intermediate-risk patients for radiotherapy. Nature Reviews. Urology, 10(8), 438–9.
- Improving care with portfolio of physician-led cancer quality measures at an academic center
  Porter, J., Smith, A. S., Winget, M., Rosenthal, E. L., Seshadri, S. B., Vetteth, Y., … Blayney, D. W. (2017). Improving care with portfolio of physician-led cancer quality measures at an academic center. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
  Kishan, A. U., Dang, A., Katz, A. J., Mantz, C. A., Collins, S. P., Aghdam, N., … King, C. R. (2019). Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA NETWORK OPEN, 2(2).
- Incorporating dosimetric features into the prediction of 3D VMAT dose distributions using deep convolutional neural network.
  Ma, M., Kovalchuk, N., Buyyounouski, M. K., Xing, L., & Yang, Y. (2019). Incorporating dosimetric features into the prediction of 3D VMAT dose distributions using deep convolutional neural network. Physics in Medicine and Biology.
- Prostate cancer classification with multiparametric MRI transfer learning model
  Yuan, Y., Qin, W., Buyyounouski, M., Ibragimov, B., Hancock, S., Han, B., & Xing, L. (2019). Prostate cancer classification with multiparametric MRI transfer learning model. MEDICAL PHYSICS, 46(2), 756–65.
- Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline
  Morgan, S. C., Hoffman, K., Loblaw, D. A., Buyyounouski, M. K., Patton, C., Barocas, D., … Sandler, H. (2018). Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. PRACTICAL RADIATION ONCOLOGY, 8(6), 354–60.
- Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
  Morgan, S. C., Hoffman, K., Loblaw, D. A., Buyyounouski, M. K., Patton, C., Barocas, D., … Sandler, H. (2018). Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. JOURNAL OF CLINICAL ONCOLOGY, 36(34), 3411-+.
- Dose Distribution Prediction in Isodose Feature-Preserving Voxelization Domain Using Deep Convolutional Neural Network.
  Ma, M., Buyyounouski, M. K., Vasudevan, V., Xing, L., & Yang, Y. (2019). Dose Distribution Prediction in Isodose Feature-Preserving Voxelization Domain Using Deep Convolutional Neural Network. Medical Physics.
- Dosimetric features-driven machine learning model for DVH prediction in VMAT treatment planning
  Ma, M., Kovalchuk, N., Buyyounouski, M. K., Xing, L., & Yang, Y. (2019). Dosimetric features-driven machine learning model for DVH prediction in VMAT treatment planning. MEDICAL PHYSICS, 46(2), 857–67.
- NCCN Guidelines (R) Insights Bladder Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines
  Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., … Gurski, L. A. (2018). NCCN Guidelines (R) Insights Bladder Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(9), 1041–53.
- Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
  Johnson, M. E., & Buyyounouski, M. K. (2012). Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy. PROSTATE CANCER.
- Continuous localization technologies for radiotherapy delivery: Report of the American Society for Radiation Oncology Emerging Technology Committee
  D'Ambrosio, D. J., Bayouth, J., Chetty, I. J., Buyyounouski, M. K., Price, R. A., Correa, C. R., … Konski, A. (2012). Continuous localization technologies for radiotherapy delivery: Report of the American Society for Radiation Oncology Emerging Technology Committee. PRACTICAL RADIATION ONCOLOGY, 2(2), 145–50.
- Multi-institutional Analysis of Prostate-Specific Antigen Kinetics Following Stereotactic Body Radiotherapy (SBRT).
  Jiang, N. Y., Dang, A. T., Yuan, Y., Chu, F.-I., Shabsovich, D., King, C. R., … Kishan, A. U. (2019). Multi-institutional Analysis of Prostate-Specific Antigen Kinetics Following Stereotactic Body Radiotherapy (SBRT). International Journal of Radiation Oncology, Biology, Physics.
- Incorporating imaging information from deep neural network layers into image guided radiation therapy (IGRT).
  Zhao, W., Han, B., Yang, Y., Buyyounouski, M., Hancock, S. L., Bagshaw, H., & Xing, L. (2019). Incorporating imaging information from deep neural network layers into image guided radiation therapy (IGRT). Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 140, 167–74.
- Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline
  Morgan, S. C., Hoffman, K., Loblaw, D. A., Buyyounouski, M. K., Patton, C., Barocas, D., … Sandler, H. (2019). Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. JOURNAL OF UROLOGY, 201(3), 528–34.
- Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer.
  Knox, S. J., Jayachandran, P., Keeling, C. A., Stevens, K. J., Sandhu, N., Stamps-DeAnda, S. L., … Grimes, K. (2019). Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer. Translational Oncology, 12(11), 1525–31.
- PROSTATE SEGMENTATION WITH ENCODER -DECODER DENSELY CONNECT CONVOLUTIONAL NETWORK (ED-DENSENET)
  Yuan, Y., Qin, W., Guo, X., Buyyounouski, M., Hancock, S., Hai, B., & Xing, L. (2019). PROSTATE SEGMENTATION WITH ENCODER -DECODER DENSELY CONNECT CONVOLUTIONAL NETWORK (ED-DENSENET). 2019 IEEE 16TH INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI 2019), 434–37.
- Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
  Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., … Johnson-Chilla, A. (2020). Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(3), 329–54.
- Incorporating dosimetric features into the prediction of 3D VMAT dose distributions using deep convolutional neural network
  Ma, M., Kovalchuk, N., Buyyounouski, M. K., Xing, L., & Yang, Y. (2019). Incorporating dosimetric features into the prediction of 3D VMAT dose distributions using deep convolutional neural network. PHYSICS IN MEDICINE AND BIOLOGY, 64(12).
- Deep learning applications in automatic needle segmentation in ultrasound-guided prostate brachytherapy.
  Wang, F., Xing, L., Bagshaw, H., Buyyounouski, M., & Han, B. (2020). Deep learning applications in automatic needle segmentation in ultrasound-guided prostate brachytherapy. Medical Physics.
- A Deep Learning Framework for Prostate Localization in Cone Beam CT Guided Radiotherapy.
  Liang, X., Zhao, W., Hristov, D. H., Buyyounouski, M. K., Hancock, S. L., Bagshaw, H., … Xing, L. (2020). A Deep Learning Framework for Prostate Localization in Cone Beam CT Guided Radiotherapy. Medical Physics.
- Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3,502 patients.
  Levin-Epstein, R., Cook, R. R., Wong, J. K., Stock, R. G., Jeffrey Demanes, D., Collins, S. P., … Kishan, A. U. (2020). Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3,502 patients. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology.
- NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer.
  Hall, W. A., Paulson, E., Davis, B. J., Spratt, D. E., Morgan, T. M., Dearnaley, D., … Lawton, C. A. (2020). NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics.
- Automatic intraprostatic lesion segmentation in multiparametric magnetic resonance images with proposed multiple branch Unet.
  Chen, Y., Xing, L., Yu, L., Bagshaw, H. P., Buyyounouski, M. K., & Han, B. (2020). Automatic intraprostatic lesion segmentation in multiparametric magnetic resonance images with proposed multiple branch Unet. Medical Physics.
- Dose-Response with Stereotactic Body Radiotherapy for Prostate Cancer: A Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics and Biochemical Control.
  Levin-Epstein, R. G., Jiang, N. Y., Wang, X., Upadhyaya, S. K., Collins, S. P., Suy, S., … Kishan, A. U. (2020). Dose-Response with Stereotactic Body Radiotherapy for Prostate Cancer: A Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics and Biochemical Control. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology.
- Automated Contour Propagation of the Prostate From pCT to CBCT Images Via Deep Unsupervised Learning.
  Liang, X., Bibault, J.-E., Leroy, T., Escande, A., Zhao, W., Chen, Y., … Xing, L. (2021). Automated Contour Propagation of the Prostate From pCT to CBCT Images Via Deep Unsupervised Learning. Medical Physics.
- PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
  Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., … Iagaru, A. (2021). PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine.
- MR to ultrasound image registration with segmentation-based learning for HDR prostate brachytherapy.
  Chen, Y., Xing, L., Yu, L., Liu, W., Fahimian, B. P., Niedermayr, T., … Han, B. (2021). MR to ultrasound image registration with segmentation-based learning for HDR prostate brachytherapy. Medical Physics.
- Development and Validation of an Interpretable Artificial Intelligence Model to Predict 10-Year Prostate Cancer Mortality
  Bibault, J.-E., Hancock, S., Buyyounouski, M. K., Bagshaw, H., Leppert, J. T., Liao, J. C., & Xing, L. (2021). Development and Validation of an Interpretable Artificial Intelligence Model to Predict 10-Year Prostate Cancer Mortality. CANCERS, 13(12).
- Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series.
  Juarez, J. E., Romero, T., Mantz, C. A., Pepin, A., Aghdam, N., Suy, S., … Kishan, A. U. (2021). Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. Advances in Radiation Oncology, 6(6), 100759.
- Refining the Definition of Biochemical Failure in the Era of Stereotactic Body Radiation Therapy for Prostate Cancer: the Phoenix Definition and Beyond.
  Martin Ma, T., Roy, S., Wu, X., Mantz, C., Fuller, D., Miszczyk, L., … Kishan, A. U. (2021). Refining the Definition of Biochemical Failure in the Era of Stereotactic Body Radiation Therapy for Prostate Cancer: the Phoenix Definition and Beyond. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology.
- Automated Contour Propagation of the Prostate From pCT to CBCT Images via Deep Unsupervised Learning
  Liang, X., Bibault, J. E., Leroy, T., Escande, A., Zhao, W., Chen, Y., … Xing, L. (2021). Automated Contour Propagation of the Prostate From pCT to CBCT Images via Deep Unsupervised Learning. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- A personalized decision aid for prostate cancer shared decision making.
  Bagshaw, H. P., Martinez, A., Heidari, N., Scheinker, D., Pollack, A., Stoyanova, R., … Buyyounouski, M. K. (1800). A personalized decision aid for prostate cancer shared decision making. BMC Medical Informatics and Decision Making, 21(1), 374.
- MR to Ultrasound Image Registration with Segmentation-Based Learning for HDR Prostate Brachytherapy
  Chen, Y., Xing, L., Yu, L., Liu, W., Fahimian, B., Niedermayr, T., … Han, B. (2021). MR to Ultrasound Image Registration with Segmentation-Based Learning for HDR Prostate Brachytherapy. MEDICAL PHYSICS. WILEY.
- Syndrome of inappropriate secretion of antidiuretic hormone following high dose rate brachytherapy for prostate cancer: a case report.
  Ayoola, A., Sodji, Q. H., Chin, S., Panousis, P., Bagshaw, H. P., & Buyyounouski, M. K. (2022). Syndrome of inappropriate secretion of antidiuretic hormone following high dose rate brachytherapy for prostate cancer: a case report. BMC Urology, 22(1), 32.
- NCCN Guidelines Insights: Bladder Cancer, Version 2.2022.
  Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Boorjian, S. A., … Gurski, L. A. (2022). NCCN Guidelines Insights: Bladder Cancer, Version 2.2022. Journal of the National Comprehensive Cancer Network : JNCCN, 20(8), 866–878.
- SALVAGE PROSTATE BRACHYTHERAPY IN RADIORECURRENT PROSTATE CANCER: AN INTERNATIONAL DELPHI CONSENSUS STUDY
  Morton, G., Chung, H. T., Corkum, M. T., Buyyounouski, M., Chang, A., Chung, P., … Kamrava, M. (2022). SALVAGE PROSTATE BRACHYTHERAPY IN RADIORECURRENT PROSTATE CANCER: AN INTERNATIONAL DELPHI CONSENSUS STUDY. RADIOTHERAPY AND ONCOLOGY. ELSEVIER IRELAND LTD.
- Long Term Results of a Phase III Randomized Prospective Trial of Erectile Tissue Sparing IMRT for Men with Clinically Localized Prostate Cancer.
  Zhang, E., Ruth, K. J., Buyyounouski, M. K., Price, R. A., Uzzo, R. G., Sobczak, M. L., … Horwitz, E. M. (2022). Long Term Results of a Phase III Randomized Prospective Trial of Erectile Tissue Sparing IMRT for Men with Clinically Localized Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics.
- Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study.
  Corkum, M. T., Buyyounouski, M. K., Chang, A. J., Chung, H. T., Chung, P., Cox, B. W., … Kamrava, M. (2023). Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 109672.
- Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
  Morgan, T. M., Boorjian, S. A., Buyyounouski, M. K., Chapin, B. F., Chen, D. Y., Cheng, H. H., … Chen, R. C. (2024). Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. The Journal of Urology, 101097JU0000000000003892.
- Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
  Morgan, T. M., Boorjian, S. A., Buyyounouski, M. K., Chapin, B. F., Chen, D. Y., Cheng, H. H., … Chen, R. C. (2024). Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. The Journal of Urology, 101097JU0000000000003890.
- Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
  Morgan, T. M., Boorjian, S. A., Buyyounouski, M. K., Chapin, B. F., Chen, D. Y., Cheng, H. H., … Chen, R. C. (2024). Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. The Journal of Urology, 101097JU0000000000003891.
- Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.
  Buyyounouski, M. K., Pugh, S. L., Chen, R. C., Mann, M. J., Kudchadker, R. J., Konski, A. A., … Sandler, H. M. (2024). Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial. JAMA Oncology.
- Bladder Cancer, Version 3.2024.
  Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Buyyounouski, M. K., … Gurski, L. A. (2024). Bladder Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network : JNCCN, 22(4), 216–225.
- Auto-delineation of treatment target volume for radiation therapy using large language model-aided multimodal learning.
  Rajendran, P., Chen, Y., Qiu, L., Niedermayr, T., Liu, W., Buyyounouski, M., … Dai, X. (2024). Auto-delineation of treatment target volume for radiation therapy using large language model-aided multimodal learning. International Journal of Radiation Oncology, Biology, Physics.
- The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction.
  Baniel, C. C., Lichter, K. E., Frick, M. A., Wu, J., Oladipo, E., Wu, Y. F., … Bagshaw, H. P. (2025). The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction. Brachytherapy.
- Automated radiotherapy treatment planning guided by GPT-4Vision.
  Liu, S., Pastor-Serrano, O., Chen, Y., Gopaulchan, M., Liang, W., Buyyounouski, M., … Xing, L. (2025). Automated radiotherapy treatment planning guided by GPT-4Vision. Physics in Medicine and Biology.
- Second-Line Radiation Therapy for Locally Recurrent Prostate Cancer After Focal Therapy: A Single Institution Matched-Pair Analysis.
  Ewongwo, A., Kalahasti, N. V., Hui, C., Taparra, K., Sonn, G., Ghanouni, P., … Buyyounouski, M. K. (2026). Second-Line Radiation Therapy for Locally Recurrent Prostate Cancer After Focal Therapy: A Single Institution Matched-Pair Analysis. Clinical Genitourinary Cancer, 24(4), 102562.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Closed Trials

Specializing In

Brachytherapy
External Beam Radiotherapy

Practice Locations

Radiation Oncology at Blake Wilbur Building Palo Alto, CA

Palo Alto, CA

Radiation Oncology at Blake Wilbur Building

875 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Urologic Cancer Program in Palo Alto Palo Alto, CA

Palo Alto, CA

Urologic Cancer Program in Palo Alto

875 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur Palo Alto, CA

Palo Alto, CA

CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur

875 Blake Wilbur Dr, Clinic D

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(106 Ratings)

Overall Rating

4.9/5

View Ratings by Category

5.0/5

Friendliness

5.0/5

Explanations

5.0/5

Listens

5.0/5

Care provider's efforts to include you in decisions about your care

5.0/5

Recommended to others

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Review Summary

Dr. Buyyounouski is known for thorough consultations and providing clear, well-explained options. Many find him knowledgeable and appreciate his friendly demeanor, which helps put people at ease. The staff is also frequently described as courteous and professional. The doctor spends time getting to know patients, and the team's expertise and kind guidance are appreciated.

The summary was created by AI, based on recent patient reviews. Learn more

Was this result useful to you?

Patient Reviews

(96 reviews)

Great doctor

Jun 2026

•

Verified SHC Patient

Very clear and to the point, Buen Trabajo

May 2026

•

Verified SHC Patient

Very professional and extremely knowledgeable about my issue

May 2026

•

Verified SHC Patient

He and his assistants did a great job of explaining everything and making me feel comfortable that they were qualified to provide my care.

May 2026

•

Verified SHC Patient

Clear communicator, compassionate and highly experienced

May 2026

•

Verified SHC Patient

Very good visit, listened carefully and developed a minimally intrusive plan, which I prefer.

May 2026

•

Verified SHC Patient

Dr. Buyyounouski is extremely knowledgeable and articulate and explained the procedure he recommended in detail. He listened carefully to my questions as did his support team. Upon leaving I felt I was in good hands and confident my future treatment will be successful. Frank Portale DDS

Apr 2026

•

Verified SHC Patient

Dr was very concerned and completed explanations of my diagnosis as well as procedures to follow.

Apr 2026

•

Verified SHC Patient

Dr Mark was very pleasant, he took his time to explain the questions I asked him, which makes to understand my situation, removes every doubt, which makes me decide to go with Stanford Medical... for my procedure.

Apr 2026

•

Verified SHC Patient

Took the time to answer all our questions and concerns as a doctor and a person instead of being detached.

Apr 2026

•

Verified SHC Patient

an excellent physician.

Mar 2026

•

Verified SHC Patient

Straightforward, professional, knowledgeable, interested in patient as person

Mar 2026

•

Verified SHC Patient

It was a pleasure dealing with him. He covered everything professionally while maintaining a very warm. pleasant persona. I feel very comfortable in his hands.

Mar 2026

•

Verified SHC Patient

It is obvious that he is very knowledgeable and experienced. He was clear and concise, explaining things in a very understandable way. He gave a very strong recommendation based on my specific circumstances.

Feb 2026

•

Verified SHC Patient

Dr. Buyyounouski is confident and knowledgeable. He was easy to talk to and was precise and direct in answering my questions. Following our video visit, I have a lot of confidence in Dr. Buyyounouski and his team to treat my prostate cancer.

Jan 2026

•

Verified SHC Patient

Great doctors, NP, and team members are all excellent. Particular appreciation to Dr. David Wu Mona, NP who often speak to. Jennifer W. is also very helpful to me navigating vaiors admin issues.

Dec 2025

•

Verified SHC Patient

Dr. Buyyounouski was very professional and also his staff. I was very impressed with his abilities.

Nov 2025

•

Verified SHC Patient

very much in tune with a patents needs , very honest answers to questions asked.

Nov 2025

•

Verified SHC Patient

Overall great experience

Oct 2025

•

Verified SHC Patient

He was great ! I'm SO glad to have him as the Dr.for me at this time !

Oct 2025

•

Verified SHC Patient

Good Heart and great explanation!

Oct 2025

•

Verified SHC Patient

Excellent communicator!

Oct 2025

•

Verified SHC Patient

Very helpful and informative.

Sep 2025

•

Verified SHC Patient

Dr. Buyyounouski and his staff did an exceptionally professional and thorough job. Dr. Buyyounouski explained my medical situation and the treatment plan well, and answered all of my questions. I also appreciated his expressed attitude that we are going for a cure of my illness.

Sep 2025

•

Verified SHC Patient

Anserwed all my questions. Is ready to take care of the problem.. Very imforative,.

Aug 2025

•

Verified SHC Patient

Straight forward and candid

Aug 2025

•

Verified SHC Patient

good repour with doctor

Jul 2025

•

Verified SHC Patient

Not much to say that hasnâ€™t been said by countless others. My opening experience at Stanford Rad Oncology was confidence inspiring. My Dr won over both my wife and meâ€¦along with his Team of pros. Thank you, Stanford

Jul 2025

•

Verified SHC Patient

EXCELLENT DOCTOR>

Jun 2025

•

Verified SHC Patient

He was very personable. He listened to my concerns and questions and effectively addressed/answered them.

May 2025

•

Verified SHC Patient

Dr. Buyyounouski has excellent communication skills. He asked me questions to verify my health status. It was very apparent he was very familiar with my case and history. He then went into great detail of the procedure he would be performing and what to expect. He impressed me by making sure I understood the thermology of the procedure. He is a great educator. The Dr. explained my future treatment plan. He did not end the conversation until he was sure I was satisfied, and any concerns were addressed. He advised me to go to "My Health at Stanford" website for written information of this visit. The Dr. told me how to get in contact with him and his staff should I have additional questions. The next day I did have a question. Three hours later I received the answer from Dr. Buyyounouski, through his staff. I was very impressed with Dr. Buyyounouski, After the appointment I felt I had the knowledge of what my day of the procedure will be like. I am very confident and feel blessed to have the care of Dr. Buyyounouski and Stanford.

May 2025

•

Verified SHC Patient

Good visit

May 2025

•

Verified SHC Patient

Super listener and explainer. Felt 100% confident in the treatment plan.

May 2025

•

Verified SHC Patient

Very helpful Very accommodating Very knowledgeable

May 2025

•

Verified SHC Patient

The physician and his entire staff were extremely courteous, professional, and knowledgeable.

Apr 2025

•

Verified SHC Patient

He explained things well and answered my questions.

Mar 2025

•

Verified SHC Patient

The best!!

Feb 2025

•

Verified SHC Patient

Thanks again. I appreciate all the information you and your staff provided me.

Jan 2025

•

Verified SHC Patient

Consult was thorough. All questions & concerns were addressed

Jan 2025

•

Verified SHC Patient

I feel very confidant in Dr Buyyounouski and look forward to our meeting on January 22.

Dec 2024

•

Verified SHC Patient

The doctor is very patient and precise which is appreciated

Dec 2024

•

Verified SHC Patient

Excellent discussion, thorough, presented the best available options and a clear plan forward.

Nov 2024

•

Verified SHC Patient

Mark was excellent!

Nov 2024

•

Verified SHC Patient

He seems to be an excellent Doctor. Very knowledgeable, friendly, great demeanor and put me at ease. We even had a few laughs which I enjoyed.

Nov 2024

•

Verified SHC Patient

Great

Nov 2024

•

Verified SHC Patient

Excellent information

Oct 2024

•

Verified SHC Patient

He spent time to know me

Sep 2024

•

Verified SHC Patient

Appeared very genuine and intuitive.

Aug 2024

•

Verified SHC Patient

The entire experience with my doctor, his assistant and the nurse was top notch!

May 2024

•

Verified SHC Patient

The Doctor and the staff that attended to me while at Stanford were above and beyound more than I expe

Feb 2024

•

Verified SHC Patient

I hope not too many others be in the same position as me at present

Feb 2024

•

Verified SHC Patient

very polite and to the point. Was good for me

Apr 2022

•

Verified SHC Patient

Direct and informative answers to all questions. He provided a link to his YouTube video which was very helpful, itâ€™s a little dated. HIs direct and efficient manner comes across as a little detached. Nurse and resident provided very good support

Mar 2022

•

Verified SHC Patient

He is a very qualified and proficient in the area of Radiation oncology.

Jan 2022

•

Verified SHC Patient

Knowledgeable doctor.

Oct 2021

•

Verified SHC Patient

top rate Doctor!

Sep 2021

•

Verified SHC Patient

He is very knowledgeable and professional doctor.

Sep 2021

•

Verified SHC Patient

A very helpful and informative video visit - doctors & staff were knowledgeable & friendly.

Sep 2021

•

Verified SHC Patient

Very much appreciated Dr. Buyyounouski's assessment and candor with his recommendation. I feel his input was directly related to my future intent and balance. The rest of the staff assisting were very helpful and very important to the process.

Jul 2021

•

Verified SHC Patient

He was thorough and very informative about the process. He explained the procedure and timeframe. He told me what to expect and when. Thanks

Jun 2021

•

Verified SHC Patient

Just appreciated the straightforward explanations and side effects of the treatment.

Jun 2021

•

Verified SHC Patient

Dr. Buyyounouski and his whole team were very knowledgeable, professional, and helpful.

May 2021

•

Verified SHC Patient

He seemed to be through he listened and he answered all questions I asked.

May 2021

•

Verified SHC Patient

Super team

May 2021

•

Verified SHC Patient

Dr. Buyyounouski answered all my questions plus gave his insight about the procedure and possible time line dates which they will confirm at a later date.

May 2021

•

Verified SHC Patient

Appreciate his cantor

May 2021

•

Verified SHC Patient

Felt very comfortable asking questions and thought the answers were on point and in a way I could understand.

Apr 2021

•

Verified SHC Patient

Doctor Mark was very informative, gave me a lot of information to consider whether to have prostate removed or.do radiation and hormone treatment. Which is what chose. He answered all my questions.. He was Very professional and made me feel at ease. His staff was also very knowledgeable. Great experience calmed my nerves. Felt like I was in good hands.

Apr 2021

•

Verified SHC Patient

Doctor plus his team were good with explanations.

Mar 2021

•

Verified SHC Patient

Excellent rapport, clarity & thoroughness.

Jan 2020

•

Verified SHC Patient

He spoke plain English and explain everything to me. No question unanswered.

Dec 2019

•

Verified SHC Patient

Really good guy.

Nov 2019

•

Verified SHC Patient

Both Dr. Buyyunouski and Dr. Miller were very thorough in explaining my options.

Sep 2019

•

Verified SHC Patient

Compared to UCSF a great experience at Stanford.

May 2019

•

Verified SHC Patient

Very professional - made me feel comfortable about the procedure.

Jan 2019

•

Verified SHC Patient

Professional.

Dec 2018

•

Verified SHC Patient

Outstanding presentation by Dr. Mark Buyyounouski.

Aug 2018

•

Verified SHC Patient

This is one of the best teams if have had to deal with. Dr. Buyyounouski is fabulous.

Aug 2018

•

Verified SHC Patient

Dr. was excellent. He answered all my questions, did not rush, took his time with me. Thank you Dr. Buyyounouski

Jul 2018

•

Verified SHC Patient

Dr. Buyyounouski and his team were all professional helpful and concerned.

Jun 2018

•

Verified SHC Patient

Dr. was a little stiff at first then he lightened of near the end.

Mar 2018

•

Verified SHC Patient

Very thorough!

Jan 2018

•

Verified SHC Patient

Dr. Mark Buyyounouski is excellent - completely thoroughly - great listener. I have complete confidence in him!

Nov 2017

•

Verified SHC Patient

Doctors & staff were great could not ask for any one better.

Sep 2017

•

Verified SHC Patient

Dr and staff didn't make us feel rushed. They allowed time to ask questions and seemed to genuinely care about my condition.

May 2017

•

Verified SHC Patient

My experience could not have been better.

Apr 2017

•

Verified SHC Patient

Very business-like, not a lot of empathy. (But I was there mainly for professional help, not emotional support.) Still, I ended up going with a different doctor who spent more time with me, and seemed much more interested in me & my case.

Mar 2017

•

Verified SHC Patient

He was excellent!

Feb 2017

•

Verified SHC Patient

The team was exceptional. Dr. B. is amazing.

Feb 2017

•

Verified SHC Patient

I was well treated and provided adequate information.

Sep 2016

•

Verified SHC Patient

All good.

Jul 2016

•

Verified SHC Patient

Dr. Buyyonouski seems very smart and also friendly & capable & concerned I liked him very much.

Jun 2016

•

Verified SHC Patient

Everyone went out of their way! Dr. Buyyounouski and all staff members life savers!!

Dec 2015

•

Verified SHC Patient

Felt like a person not a number.

Aug 2015

•

Verified SHC Patient

Very good.

Jan 2015

•

Verified SHC Patient

Great doctor!

Jun 2014

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Mark Buyyounouski, MD, MS, FASTRO

Radiation oncologist, Genitourinary specialist

Get In Touch

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Radiation Oncology at Blake Wilbur Building Palo Alto, CA

Radiation Oncology at Blake Wilbur Building

Urologic Cancer Program in Palo Alto Palo Alto, CA

Urologic Cancer Program in Palo Alto

CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur Palo Alto, CA

CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Review Summary

Patient Reviews

(96 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Mark Buyyounouski, MD, MS, FASTRO

Radiation oncologist, Genitourinary specialist

Get In Touch

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Radiation Oncology at Blake Wilbur Building Palo Alto, CA

Radiation Oncology at Blake Wilbur Building

Urologic Cancer Program in Palo Alto Palo Alto, CA

Urologic Cancer Program in Palo Alto

CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur Palo Alto, CA

CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Review Summary

Patient Reviews

(96 reviews)

Referring Physicians

PHYSICIAN HELPLINE